Shares of Dermira Inc (NASDAQ:DERM) shot up 5.4% during mid-day trading on Monday . The stock traded as high as $8.52 and last traded at $7.55, 121,796 shares were traded during mid-day trading. A decline of 85% from the average session volume of 829,551 shares. The stock had previously closed at $7.16.
Several research firms recently issued reports on DERM. Zacks Investment Research raised Dermira from a “hold” rating to a “strong-buy” rating and set a $6.50 price objective on the stock in a research report on Wednesday, October 9th. BidaskClub raised Dermira from a “strong sell” rating to a “sell” rating in a research report on Saturday. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Dermira in a research report on Friday. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $17.36.
The firm has a fifty day moving average price of $7.19 and a two-hundred day moving average price of $9.13. The stock has a market capitalization of $309.52 million, a P/E ratio of -1.39 and a beta of 1.32. The company has a debt-to-equity ratio of 4.95, a quick ratio of 8.08 and a current ratio of 8.42.
In related news, CEO Thomas G. Wiggans acquired 23,419 shares of Dermira stock in a transaction dated Monday, August 19th. The stock was purchased at an average cost of $8.54 per share, for a total transaction of $199,998.26. Following the purchase, the chief executive officer now directly owns 39,666 shares of the company’s stock, valued at approximately $338,747.64. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Matthew K. Fust sold 6,000 shares of the company’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $8.77, for a total value of $52,620.00. Following the completion of the sale, the director now owns 11,051 shares of the company’s stock, valued at $96,917.27. The disclosure for this sale can be found here. Corporate insiders own 12.40% of the company’s stock.
Large investors have recently bought and sold shares of the company. Point72 Hong Kong Ltd increased its stake in shares of Dermira by 124.2% in the 2nd quarter. Point72 Hong Kong Ltd now owns 4,170 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 2,310 shares in the last quarter. Bank of Montreal Can increased its stake in shares of Dermira by 621.8% in the 2nd quarter. Bank of Montreal Can now owns 4,533 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 3,905 shares in the last quarter. Advisor Group Inc. increased its stake in shares of Dermira by 41.7% in the 2nd quarter. Advisor Group Inc. now owns 8,589 shares of the biopharmaceutical company’s stock worth $83,000 after purchasing an additional 2,527 shares in the last quarter. Atria Investments LLC purchased a new stake in Dermira in the 2nd quarter worth $85,000. Finally, Fox Run Management L.L.C. purchased a new stake in Dermira in the 2nd quarter worth $120,000. Hedge funds and other institutional investors own 94.51% of the company’s stock.
Dermira Company Profile (NASDAQ:DERM)
Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.
Read More: How To Calculate Debt-to-Equity Ratio
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.